Plain Language Summary: the GARNET study, dostarlimab for the treatment of endometrial cancer
This Plain Language Summary of Publication from Future Oncology looks at a medication called dostarlimab for the treatment of endometrial cancer. This summary describes results from an ongoing study , called GARNET, that is testing the safety and side effects of dostarlimab and the best way to administer it to patients.
Read the full article here.
The original article which this summary is based on is called ‘Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study’. It was published in the Journal for Immunotherapy of Cancer.
You can read it here.